Trial reportThe Journal of clinical endocrinology and metabolism2010
Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement.
Trial report in The Journal of clinical endocrinology and metabolism, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00182091 (Effects of Physiologic Growth Hormone Administration on Cardiovascular Risk in Subjects With Growth Hormone Deficiency Following Cure of Acromegaly), which is not on this map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Physiologic Growth Hormone Administration on Cardiovascular Risk in Subjects With Growth Hormone Deficiency Following Cure of Acromegaly
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Anxiety, depression and acromegaly: a systematic review.Journal of endocrinological investigation · 2025Pooled it
- Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies.Pituitary · 2015Pooled it
- Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial.European journal of endocrinology · 2012Trial
- Effect of growth hormone replacement therapy on the quality of life in women with growth hormone deficiency who have a history of acromegaly versus other disorders.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical EndocrinologistsTrial
- Liver steatosis and fibrosis in acromegaly patients with active and controlled disease: a scoping review.Journal of endocrinological investigation · 2026Review
- Clinical Management of Postoperative Growth Hormone Deficiency in Hypothalamic-Pituitary Tumors.Journal of clinical medicine · 2024Review
- Long-Term Safety of Growth Hormone Deficiency Treatment in Cancer and Sellar Tumors Adult Survivors: Is There a Role of GH Therapy on the Neoplastic Risk?Journal of clinical medicine · 2023Review
- Adult Growth Hormone Deficiency: Diagnostic and Treatment Journeys From the Patients' Perspective.Journal of the Endocrine Society · 2022Article
- Article
- Review
- Growth hormone therapy in adults with growth hormone deficiency: a critical assessment of the literature.Pituitary · 2020Review
- Article
- Review
- Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters.Frontiers in endocrinology · 2017Review
- The Role of the Growth Hormone/Insulin-Like Growth Factor System in Visceral Adiposity.Biochemistry insights · 2017Review
- Effect of growth hormone treatment on diastolic function in patients who have developed growth hormone deficiency after definitive treatment of acromegaly.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2016Observational
- Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2015Review
- Short-term efficacy of recombinant human GH therapy in cured acromegaly patients with GH deficiency: a single-center experience.Endocrine connections · 2015Article
- Article
- Improving Quality of Life in Patients with Pituitary Tumours.European endocrinology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
contextThe effects of GH replacement therapy in patients who develop GH deficiency (GHD) after cure of acromegaly have not been established in a placebo-controlled study.
objectiveThe objective of the study was to determine whether GH replacement improves body composition, cardiovascular risk markers and quality of life in patients with GHD and prior acromegaly.
designThis was a 6-month, randomized, placebo-controlled study.
settingThe study was conducted at a clinical translational science center. STUDY
participantsParticipants included 30 subjects with prior acromegaly and current GHD.
interventionINTERVENTIONs included GH or placebo.
main outcome measuresBody composition (dual-energy x-ray absorptiometry and cross-sectional computed tomography at L4), cardiovascular risk markers (high-sensitivity C-reactive protein (hsCRP), total, high-density lipoprotein and low-density lipoprotein cholesterol, fibrinogen, and carotid intimal-medial thickness), and quality of life were measured.
resultsThe mean GH dose at 6 months was 0.58 +/- 0.26 mg/d. Total fat mass, visceral adipose tissue (-15.3 +/- 18.6 vs. 1.3 +/- 12.5%, P = 0.01), and total abdominal fat decreased, and fat-free mass increased, in the GH vs. placebo group. Mean hsCRP levels decreased, but there was no GH effect on other cardiovascular risk markers. There was no change in glycosylated hemoglobin or homeostasis model assessment insulin resistance index. Quality of life improved with GH. Side effects were minimal.
conclusionsThis is the first randomized, placebo-controlled study of the effects of GH replacement therapy on body composition and cardiovascular end points in patients who have developed GH deficiency after treatment for acromegaly, a disease complicated by metabolic and body composition alterations and increased cardiovascular risk. GH replacement decreased visceral adipose tissue, increased fat-free mass, decreased hsCRP, and improved quality of life in patients with GHD after cure of acromegaly, with minimal side effects and without an increase in insulin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.